Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To compare the efficacy of ipragliflozin versus pioglitazone in patients with type 2 diabetes complicated by nonalcoholic fatty liver disease (NAFLD).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Diabetes Care

Title: Diabetes care

Publisher: American Diabetes Association

ISSN (Electronic): 1935-5548

ISSN (Print): 0149-5992

Publication date (Electronic): October 2017

Volume: 40

Issue: 10

Affiliations

[1 ] Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan dito@saitama-med.ac.jp.

[2 ] Department of Internal Medicine, Ogawa Red Cross Hospital, Saitama, Japan.

[3 ] Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.

[4 ] Satsuki Medical Clinic, Saitama, Japan.

[5 ] Department of Diabetes and Endocrinology, Higashiyamato Hospital, Tokyo, Japan.

Article

Publisher Item ID: dc17-0518

DOI: 10.2337/dc17-0518

PubMed ID: 28751548

SO-VID: 5e1eb1f3-77b3-4ada-a887-b1af47f30be9

History

Keywords: SGLT2 inhibitor

Data availability:

Keywords: SGLT2 inhibitor

Comments

Comment on this article

scite_

Cited by 137

See all cited by